(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 8.41% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Neogenomics's revenue in 2026 is $766,295,000.On average, 13 Wall Street analysts forecast NEO's revenue for 2026 to be $104,327,196,298, with the lowest NEO revenue forecast at $100,661,791,994, and the highest NEO revenue forecast at $108,647,825,345. On average, 13 Wall Street analysts forecast NEO's revenue for 2027 to be $114,881,453,694, with the lowest NEO revenue forecast at $110,847,324,878, and the highest NEO revenue forecast at $121,813,988,436.
In 2028, NEO is forecast to generate $125,428,002,563 in revenue, with the lowest revenue forecast at $120,856,846,408 and the highest revenue forecast at $131,944,276,880.